Press Releases Calidi Biotherapeutics, Inc.

Equities

CLDI

US3207031010

Market Closed - Nyse Other stock markets 01:30:00 17/05/2024 am IST			5-day change	1st Jan Change
0.242 ^USD	+3.60%		+1.26%	-83.97%

16/04	Calidi Biotherapeutics Prices $6.1 Million Offering	MT
21/03	H.C. Wainwright Lowers Price Target on Calidi Biotherapeutics to $2 From $11, Maintains Buy Rating	MT

Press Releases

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Calidi Biotherapeutics Reports First Quarter 2024 Operating and Financial Results	15/05	BU
Calidi Biotherapeutics Announces Upcoming Presentations at the 2024 ASCO Annual Meeting	01/05	BU
Join Calidi Biotherapeutics Exclusive Live Investor Webinar and Q&A Session on April 24	24/04	AQ
Join Calidi Biotherapeutics’ Exclusive Live Investor Webinar and Q&A Session on April 24	23/04	BU
Calidi Biotherapeutics, Inc. Announces Closing of $6.1 Million Public Offering	20/04	BU
Calidi Biotherapeutics, Inc. Announces Pricing of $6.1 Million Public Offering	16/04	BU
Calidi Biotherapeutics Presents New Data on the Mechanisms of Action for Virotherapy-Loaded Stem Cells Used in the Company's Novel Immunotherapies at the AACR Annual Meeting 2024	10/04	AQ
Calidi Biotherapeutics Presents New Data on the Mechanisms of Action for Virotherapy-Loaded Stem Cells Used in the Company’s Novel Immunotherapies at the AACR Annual Meeting 2024	09/04	BU
Calidi Biotherapeutics Reports Fourth Quarter and Full-Year 2023 Operating and Financial Results	16/03	BU
Calidi Biotherapeutics and City of Hope Announce Funding from the California Institute for Regenerative Medicine (CIRM) to Advance CLD-101 (NeuroNova) in Ovarian Cancer	11/03	BU
Calidi Biotherapeutics to Highlight Novel Systemic Enveloped Oncolytic Virotherapy Platform Designed to Target All Tumor Sites at Upcoming Conference	12/02	BU
Calidi Biotherapeutics Announces the Appointment of Three New Members to its Scientific and Medical Advisory Board	08/01	BU
Calidi Biotherapeutics Announces Appointment of Pharmaceutical Industry Veteran David LaPre to its Board of Directors	13/12	AQ
Calidi Biotherapeutics Announces Presentation of Clinical Study for NeuroNova with Recurrent High Grade Glioma at the 8th Oncolytic Virotherapy Summit	13/12	BU
Calidi Biotherapeutics Announces Appointment of Pharmaceutical Industry Veteran David LaPré to its Board of Directors	12/12	BU
Calidi Biotherapeutics Announces Issuance of New U.S. Patent Covering Novel SuperNova Technology Platform and Updates Anticipated Clinical Milestones	20/11	BU
Calidi Biotherapeutics Reports Third Quarter 2023 Operating and Financial Result	15/11	AQ
Calidi Biotherapeutics Reports Third Quarter 2023 Operating and Financial Results	15/11	BU
Calidi Biotherapeutics (NYSEAM: CLDI) Presents Data on CLD-201 Demonstrating Inhibition of Tumor Growth and Induction of Robust Anti-Tumor Immunity at the Society for Immunotherapy of Cancer’s 38th Annual Meeting (SITC 2023)	03/11	BU
Calidi Biotherapeutics Announces Key Leadership Promotions and New Board Appointment	01/11	BU

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases Calidi Biotherapeutics, Inc.

Equities

CLDI

US3207031010

Press Releases

Filters